Inhibition of disheveled-2 resensitizes cisplatin-resistant lung cancer cells through down-regulating Wnt/β-catenin signaling

Experimental Cell Research

Volumn 347, Issue 1, 2016, Pages 105-113

  Luo, Ke ^a   Gu, Xiuhui ^a   Liu, Jing ^a   Zeng, Guodan ^a   Peng, Liaotian ^a   Huang, Houyi ^a   Jiang, Mengju ^a   Yang, Ping ^a   Li, Minhui ^a   Yang, Yuhan ^a   Wang, Yuanyuan ^a   Peng, Quekun ^a   Zhu, Li ^b   Zhang, Kun ^a  

^a CHENGDU MEDICAL COLLEGE   (China)

^b FIRST AFFILIATED HOSPITAL   (China)

Author keywords

Cisplatin; Disheveled; Lung cancer; Resistance; Wnt catenin

Indexed keywords

BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DISHEVELLED 2; GLYCOGEN SYNTHASE KINASE 3BETA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; SURVIVIN; WNT PROTEIN; DISHEVELLED PROTEIN; TUMOR PROTEIN;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; LUNG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; A-549 CELL LINE; CELL NUCLEUS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; WNT SIGNALING PATHWAY;

A549 CELLS; BETA CATENIN; CELL NUCLEUS; CISPLATIN; DISHEVELLED PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROTEIN TRANSPORT; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84979609932     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2016.07.014     Document Type: Article

References (56)

1. [1] Ganesh, S., Iyer, A.K., Weiler, J., Morrissey, D.V., Amiji, M.M., Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol. Ther. Nucleic Acids, 2, 2013, e110.
2. [2] Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA Cancer J. Clin. 60 (2010), 277–300.
3. [3] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J. Clin. 61 (2011), 69–90.
4. [4] Wu, W.J., Zhang, Y., Zeng, Z.L., Li, X.B., Hu, K.S., Luo, H.Y., Yang, J., Huang, P., Xu, R.H., beta-phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype. Biochem. Pharm. 85 (2013), 486–496.
5. [5] Yang, Y., Li, H., Hou, S., Hu, B., Liu, J., Wang, J., The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One, 8, 2013, e65309.
6. [6] Rose, M.C., Kostyanovskaya, E., Huang, R.S., Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. Genom. Proteom. Bioinform. 12 (2014), 198–209.
7. [7] Dasari, S., Tchounwou, P.B., Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharm. 740 (2014), 364–378.
8. [8] Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., Kroemer, G., Molecular mechanisms of cisplatin resistance. Oncogene 31 (2012), 1869–1883.
9. [9] Xiong, F., Jiang, M., Huang, Z., Chen, M., Chen, K., Zhou, J., Yin, L., Tang, Y., Wang, M., Ye, L., Zhan, Z., Duan, J., Fu, H., Zhang, X., A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells. Integr. Cancer Ther. 13 (2014), 152–160.
10. [10] Wang, K., Li, N., Yeung, C.H., Li, J.Y., Wang, H.Y., Cooper, T.G., Oncogenic Wnt/beta-catenin signalling pathways in the cancer-resistant epididymis have implications for cancer research. Mol. Hum. Reprod. 19 (2013), 57–71.
11. [11] Prakash, S., Swaminathan, U., Beta catenin in health: a review. J. Oral Maxillofac. Pathol. 19 (2015), 230–238.
12. [12] Clevers, H., Nusse, R., Wnt/beta-catenin signaling and disease. Cell 149 (2012), 1192–1205.
13. [13] Ashihara, E., Takada, T., Maekawa, T., Targeting the canonical Wnt/beta-catenin pathway in hematological malignancies. Cancer Sci. 106 (2015), 665–671.
14. [14] Vilchez, V., Turcios, L., Marti, F., Gedaly, R., Targeting Wnt/beta-catenin pathway in hepatocellular carcinoma treatment. World J. Gastroenterol. 22 (2016), 823–832.
15. [15] Cavard, C., Colnot, S., Audard, V., Benhamouche, S., Finzi, L., Torre, C., Grimber, G., Godard, C., Terris, B., Perret, C., Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol. 4 (2008), 647–660.
16. [16] Schwarz-Romond, T., Metcalfe, C., Bienz, M., Dynamic recruitment of axin by Dishevelled protein assemblies. J. Cell Sci. 120 (2007), 2402–2412.
17. [17] Gao, C., Chen, Y.G., Dishevelled: the hub of Wnt signaling. Cell. Signal. 22 (2010), 717–727.
18. [18] Smalley, M.J., Signoret, N., Robertson, D., Tilley, A., Hann, A., Ewan, K., Ding, Y., Paterson, H., Dale, T.C., Dishevelled (Dvl-2) activates canonical Wnt signalling in the absence of cytoplasmic puncta. J. Cell Sci. 118 (2005), 5279–5289.
19. [19] Pulvirenti, T., Van Der Heijden, M., Droms, L.A., Huse, J.T., Tabar, V., Hall, A., Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res. 71 (2011), 7280–7290.
20. [20] Metcalfe, C., Ibrahim, A.E., Graeb, M., de la Roche, M., Schwarz-Romond, T., Fiedler, M., Winton, D.J., Corfield, A., Bienz, M., Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer. Cancer Res. 70 (2010), 6629–6638.
21. [21] Zhu, Y., Tian, Y., Du, J., Hu, Z., Yang, L., Liu, J., Gu, L., Dvl2-dependent activation of Daam1 and RhoA regulates Wnt5a-induced breast cancer cell migration. PLoS One, 7, 2012, e37823.
22. [22] Narimatsu, M., Bose, R., Pye, M., Zhang, L., Miller, B., Ching, P., Sakuma, R., Luga, V., Roncari, L., Attisano, L., Wrana, J.L., Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell 137 (2009), 295–307.
23. [23] Zhang, K., Song, H., Yang, P., Dai, X., Li, Y., Wang, L., Du, J., Pan, K., Zhang, T., Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3beta/beta-catenin signalling. Cell Prolif. 48 (2015), 249–258.
24. [24] Gao, Y., Liu, Z., Zhang, X., He, J., Pan, Y., Hao, F., Xie, L., Li, Q., Qiu, X., Wang, E., Inhibition of cytoplasmic GSK-3beta increases cisplatin resistance through activation of Wnt/beta-catenin signaling in A549/DDP cells. Cancer Lett. 336 (2013), 231–239.
25. [25] Chikazawa, N., Tanaka, H., Tasaka, T., Nakamura, M., Tanaka, M., Onishi, H., Katano, M., Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res. 30 (2010), 2041–2048.
26. [26] Lim, J.C., Kania, K.D., Wijesuriya, H., Chawla, S., Sethi, J.K., Pulaski, L., Romero, I.A., Couraud, P.O., Weksler, B.B., Hladky, S.B., Barrand, M.A., Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J. Neurochem. 106 (2008), 1855–1865.
27. [27] Li, C., Zhou, C., Wang, S., Feng, Y., Lin, W., Lin, S., Wang, Y., Huang, H., Liu, P., Mu, Y.G., Shen, X., Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3beta/beta-catenin signaling pathway. PLoS One, 6, 2011, e27053.
28. [28] Fung, T.K., Gandillet, A., So, C.W., Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/beta-catenin pathway. Curr. Opin. Hematol. 19 (2012), 280–286.
29. [29] Fennell, D.A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D.C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., Ferry, D., Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat. Rev. 44 (2016), 42–50.
30. [30] Rossi, A., Di Maio, M., Chiodini, P., Rudd, R.M., Okamoto, H., Skarlos, D.V., Fruh, M., Qian, W., Tamura, T., Samantas, E., Shibata, T., Perrone, F., Gallo, C., Gridelli, C., Martelli, O., Lee, S.M., Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J. Clin. Oncol. 30 (2012), 1692–1698.
31. [31] Amable, L., Cisplatin resistance and opportunities for precision medicine. Pharm. Res 106 (2016), 27–36.
32. [32] Wu, T., Wang, M.C., Jing, L., Liu, Z.Y., Guo, H., Liu, Y., Bai, Y.Y., Cheng, Y.Z., Nan, K.J., Liang, X., Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Des. Dev. Ther. 9 (2015), 6421–6431.
33. [33] Zhang, D., Ochi, N., Takigawa, N., Tanimoto, Y., Chen, Y., Ichihara, E., Hotta, K., Tabata, M., Tanimoto, M., Kiura, K., Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer Lett. 309 (2011), 228–235.
34. [34] Wang, T., Liu, Z., Shi, F., Wang, J., Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/beta-catenin signaling pathway in cervical cancer. Mol. Cell. Biochem. 413 (2016), 179–187.
35. [35] Stewart, D.J., Chang, D.W., Ye, Y., Spitz, M., Lu, C., Shu, X., Wampfler, J.A., Marks, R.S., Garces, Y.I., Yang, P., Wu, X., Wnt signaling pathway pharmacogenetics in non-small cell lung cancer. Pharm. J. 14 (2014), 509–522.
36. [36] Bilic, J., Huang, Y.L., Davidson, G., Zimmermann, T., Cruciat, C.M., Bienz, M., Niehrs, C., Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science 316 (2007), 1619–1622.
37. [37] Kafka, A., Basic-Kinda, S., Pecina-Slaus, N., The cellular story of dishevelleds. Croat. Med. J. 55 (2014), 459–467.
38. [38] Schwarz-Romond, T., Fiedler, M., Shibata, N., Butler, P.J., Kikuchi, A., Higuchi, Y., Bienz, M., The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat. Struct. Mol. Biol. 14 (2007), 484–492.
39. [39] Metcalfe, C., Mendoza-Topaz, C., Mieszczanek, J., Bienz, M., Stability elements in the LRP6 cytoplasmic tail confer efficient signalling upon DIX-dependent polymerization. J. Cell Sci. 123 (2010), 1588–1599.
40. [40] You, L., Xu, Z., Punchihewa, C., Jablons, D.M., Fujii, N., Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcription. Mol. Cancer Ther. 7 (2008), 1633–1638.
41. [41] Zhu, Y., Shen, T., Liu, J., Zheng, J., Zhang, Y., Xu, R., Sun, C., Du, J., Chen, Y., Gu, L., Rab35 is required for Wnt5a/Dvl2-induced Rac1 activation and cell migration in MCF-7 breast cancer cells. Cell. Signal. 25 (2013), 1075–1085.
42. [42] Kafka, A., Tomas, D., Beros, V., Pecina, H.I., Zeljko, M., Pecina-Slaus, N., Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin. Int. J. Mol. Sci. 15 (2014), 10635–10651.
43. [43] Grandy, D., Shan, J., Zhang, X., Rao, S., Akunuru, S., Li, H., Zhang, Y., Alpatov, I., Zhang, X.A., Lang, R.A., Shi, D.L., Zheng, J.J., Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem. 284 (2009), 16256–16263.
44. [44] Dlugosz, A., Janecka, A., ABC transporters in the development of multidrug resistance in cancer therapy. Curr. Pharm. Des., 2016.
45. [45] Zhang, K., Yang, H., Wang, Y., Ma, L., Zhou, Q., Expression and significance of nrf2 and its target genes in pulmonary adenocarcinoma a549 cells resistant to Cisplatin. Zhongguo Fei Ai ZA Zhi 12 (2009), 1150–1154.
46. [46] Yoh, K., Ishii, G., Yokose, T., Minegishi, Y., Tsuta, K., Goto, K., Nishiwaki, Y., Kodama, T., Suga, M., Ochiai, A., Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin. Cancer Res. 10 (2004), 1691–1697.
47. [47] Hwang, J.S., Lee, H.C., Oh, S.C., Lee, D.H., Kwon, K.H., Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin. Tumour Biol. 36 (2015), 8819–8829.
48. [48] Lee, S.C., Kim, O.H., Lee, S.K., Kim, S.J., IWR-1 inhibits epithelial-mesenchymal transition of colorectal cancer cells through suppressing Wnt/beta-catenin signaling as well as survivin expression. Oncotarget 6 (2015), 27146–27159.
49. [49] Tian, J., He, H., Lei, G., Wnt/beta-catenin pathway in bone cancers. Tumour Biol. 35 (2014), 9439–9445.
50. [50] Yamamoto, H., Ngan, C.Y., Monden, M., Cancer cells survive with survivin. Cancer Sci. 99 (2008), 1709–1714.
51. [51] Wang, N., Wang, Z., Peng, C., You, J., Shen, J., Han, S., Chen, J., Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via beta-catenin/ABCG2 signaling. Carcinogenesis 35 (2014), 2544–2554.
52. [52] Chau, W.K., Ip, C.K., Mak, A.S., Lai, H.C., Wong, A.S., c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene 32 (2013), 2767–2781.
53. [53] Caracci, M.O., Avila, M.E., De Ferrari, G.V., Synaptic Wnt/GSK3beta signaling hub in autism. Neural Plast., 2016, 9603751.
54. [54] Cohen, P., Frame, S., The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2 (2001), 769–776.
55. [55] Saifo, M.S., Rempinski, D.R. Jr., Rustum, Y.M., Azrak, R.G., Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers. Mol. Cancer, 9, 2010, 310.
56. [56] Gan, X.Q., Wang, J.Y., Xi, Y., Wu, Z.L., Li, Y.P., Li, L., Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction. J. Cell Biol. 180 (2008), 1087–1100.